Registration No. 333-292779 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 As filed with the Securities and Exchange Commission on January 29, 2026. REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SpyGlass Pharma, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 83-3044245 (I.R.S. Employer Identification ...

Core Viewpoint - Harrow, a leading provider of ophthalmic disease management solutions in North America, will report its third-quarter financial results on November 10, 2025, and host a conference call on November 11, 2025, to discuss these results and provide a business update [1]. Company Overview - Harrow, Inc. (Nasdaq: HROW) specializes in ophthalmic disease management, offering a comprehensive portfolio of products for conditions affecting the eye, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [3]. - The company is committed to delivering safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes [3]. Conference Call Information - The conference call will be accessible via a live webcast on Harrow's "Investors" page, with a replay available for one year [2]. - Participants can join the call by registering in advance to receive a unique dial-in number and PIN [2].